Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment (DCE)

2. juni 2022 opdateret af: Bristol-Myers Squibb

Patient Preference for Treatment of Moderate-To-Severe Psoriasis in Japan

The purpose of this observational study is to identify and weight the treatment attributes from the moderate-to-severe Psoriasis (PsO) patients' perspective in Japan.

Studieoversigt

Status

Afsluttet

Betingelser

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

232

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Forenede Stater
    • North Carolina
      • Morrisville, North Carolina, Forenede Stater, 27560
        • Local Institution

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

20 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

A total of 10 participants, diagnosed as moderate-to-severe Psoriasis (PsO) by a clinician were included in the Phase 1 qualitative interview

A total of 200 participants, self-reported as moderate-to-severe PsO, were included in the Phase 2 online survey

Beskrivelse

Inclusion Criteria:

  • Diagnosis of moderate-to-severe Psoriasis (PsO) by physician (phase 1) or self-reported (phase 2)
  • Currently taking systemic psoriasis treatment
  • Japanese resident aged 20 years and older

Exclusion Criteria:

  • Unable or unwilling to provide informed consent
  • Diagnosis of guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Phase 1
Participants with moderate-to-severe Psoriasis (PsO) in Japan who have been recruited based on eligibility criteria
Phase 2
Self-reported moderate-to-severe Psoriasis (PsO) participants in Japan

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Psoriasis (PsO) patient preferences of moderate-to-severe systemic treatment atrribute
Tidsramme: Within 60 minutes of survey/interview
Within 60 minutes of survey/interview
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 1: Sex
Tidsramme: At Baseline
At Baseline
Distribution of socio-demographic characteristics of PsO participants in Phase 1: Age
Tidsramme: At Baseline
At Baseline
Distribution of clinical characteristics of PsO participants in Phase 1: Time since PsO diagnosis
Tidsramme: At Baseline
At Baseline
Distribution of clinical characteristics of PsO participants in Phase 1: Severity of PsO
Tidsramme: At Baseline
At Baseline
Distribution of clinical characteristics of PsO participants in Phase 1: Current treatments for PsO
Tidsramme: At Baseline
At Baseline
Distribution of clinical characteristics of PsO participants in Phase 1: Time on current PsO treatment
Tidsramme: At Baseline
At Baseline
Distribution of socio-demographic characteristics of PsO participants in Phase 1: Residence
Tidsramme: At Baseline
At Baseline
Distribution of socio-demographic characteristics of PsO participants in Phase 1: Employment status
Tidsramme: At Baseline
At Baseline
Distribution of socio-demographic characteristics of PsO participants in Phase 1: Education
Tidsramme: At Baseline
At Baseline
Distribution of clinical characteristics of PsO participants in Phase 1: Total number of previous treatments
Tidsramme: At Baseline
At Baseline
Distribution of clinical characteristics of PsO participants in Phase 1: Previous treatments for PsO
Tidsramme: At Baseline
At Baseline
Distribution of socio-demographic characteristics of PsO participants in Phase 1: Level of income
Tidsramme: At Baseline
At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Sex
Tidsramme: At Baseline
At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Age
Tidsramme: At Baseline
At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Height
Tidsramme: At Baseline
At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Weight
Tidsramme: At Baseline
At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Residence
Tidsramme: At Baseline
At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Employment status
Tidsramme: At Baseline
At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Type of occupation
Tidsramme: At Baseline
At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Education
Tidsramme: At Baseline
At Baseline
Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Time since PsO diagnosis
Tidsramme: At Baseline
At Baseline
Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Self-reported severity
Tidsramme: At Baseline
At Baseline
Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Current treatments for PsO
Tidsramme: At Baseline
At Baseline
Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Time on current PsO treatment
Tidsramme: At Baseline
At Baseline
Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Previous treatments for PsO
Tidsramme: At Baseline
At Baseline
Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Comorbid conditions of interest
Tidsramme: At Baseline
At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Level of income
Tidsramme: At Baseline
At Baseline

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Bristol-Myers Squibb

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. oktober 2021

Primær færdiggørelse (Faktiske)

7. februar 2022

Studieafslutning (Faktiske)

7. februar 2022

Datoer for studieregistrering

Først indsendt

23. september 2021

Først indsendt, der opfyldte QC-kriterier

23. september 2021

Først opslået (Faktiske)

4. oktober 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. juni 2022

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. juni 2022

Sidst verificeret

1. maj 2022

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • IM011-174

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Psoriasis

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Cyprus

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

3
Abonner